top of page
The Professional Network for Healthcare Experts
Orion Pharma and Qilu partner on pembrolizumab biosimilar for Europe
Orion Pharma and Qilu Pharma Europe have entered a European commercialisation agreement for a proposed intravenous pembrolizumab biosimilar.
nuaxia
Oct 72 min read
FDA approves Teva's DEGEVMA biosimilar to Xgeva across all reference-product indications
The FDA has approved Teva's DEGEVMA as a biosimilar to Xgeva across all reference-product indications, expanding competition in denosumab treatment.
nuaxia
Sep 291 min read
Sandoz and mAbxience partner on global emicizumab biosimilar programme
Sandoz and mAbxience have entered a global collaboration to develop, manufacture and commercialise a proposed biosimilar to Roche's haemophilia medicine Hemlibra.
nuaxia
Sep 222 min read
Henlius receives Pakistan approval for adalimumab biosimilar HANDAYUAN
Henlius has received approval in Pakistan for HANDAYUAN, its adalimumab biosimilar, marking the product's first regulatory approval outside China.
nuaxia
Sep 171 min read
Lupin receives Indian marketing approval for pegfilgrastim biosimilar
Lupin has received Indian marketing approval for a pegfilgrastim biosimilar used to reduce the risk of chemotherapy-induced neutropenia.
nuaxia
Sep 111 min read
Cipla licenses Qilu's Keytruda biosimilar for the US
The agreement gives Cipla exclusive US commercialisation rights to Qilu Pharmaceutical's pembrolizumab biosimilar candidate QL2107, referencing Keytruda.
nuaxia
Sep 42 min read
Samsung Bioepis gains Japanese approval for intravenous Stelara biosimilar
Samsung Bioepis has received Japanese marketing approval for a 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara.
nuaxia
Sep 41 min read
bottom of page